NEW YORK, May 11 - Merck's $620 million acquisition of Rosetta will bring all of Rosetta's research and development efforts under the control of Merck's management, but won't affect Rosetta's Resolver business, a Rosetta spokeswoman told GenomeWeb.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.